U.S. Markets open in 3 hrs 35 mins

Oncolytics Biotech Inc. (ONC.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
0.50+0.01 (+2.04%)
At close: 3:59PM EDT
Full screen
Previous Close0.49
Bid0.48 x 0
Ask0.51 x 0
Day's Range0.48 - 0.50
52 Week Range0.19 - 1.13
Avg. Volume318,703
Market Cap69.71M
PE Ratio (TTM)-4.13
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks Small Cap Research7 days ago

    Oncolytics’ (ONCYF) Second Quarter Results

    Oncolytics Biotech, Incorporated’s (ONCYF) second quarter began with a rush of activity as the company presented compelling data from its IND 213 study at AACR followed by an announcement of fast track designation by the FDA and presentation at ASCO in May.  The strong data from the metastatic breast cancer trial indicated a 17 month benefit from REOLYSIN (compared to 10 months for chemotherapy alone) and opens the opportunity for breakthrough designation which could be announced in October.  In preparation for a Phase III trial, Oncolytics raised additional capital in May which is expected to fund operations until late next year. The second half of 2017 will emphasize the interactions with the FDA and how this will impact the design of the Phase III trial for metastatic breast cancer.  There is also the possibility to receive breakthrough designation which will expedite the FDA’s review of REOLYSIN.  Potential collaborators are watching this process closely and we anticipate that there will be more to announce regarding a partner for the Phase III trial before the end of the year.

  • Associated Press17 days ago

    Oncolytics reports 2Q loss

    On a per-share basis, the Calgary, Alberta-based company said it had a loss of 2 cents. The company's shares closed at 40 cents. A year ago, they were trading at 32 cents. _____ This story was generated ...

  • Zacks Small Cap Research2 months ago

    Oncolytics (ONCYF) Raises CAD$11 Million

    By John Vandermosten, CFA OTC:ONCYF Public Offering of Shares Strengthens Balance Sheet In late May, 2017, Oncolytics Biotech, Inc. (OTC:ONCYF) announced and priced 16.4 million units at CAD$0.70 per share ...